These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32269005)

  • 1. A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia.
    Nakonezny PA; Lindow JC; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Byerly MJ
    Schizophr Res; 2020 Jun; 220():92-97. PubMed ID: 32269005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 3. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.
    Byerly MJ; Nakonezny PA; Rush AJ
    Schizophr Res; 2008 Mar; 100(1-3):60-9. PubMed ID: 18255269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.
    Kishimoto T; Sanghani S; Russ MJ; Marsh AN; Morris J; Basu S; John M; Kane JM
    Int Clin Psychopharmacol; 2017 May; 32(3):161-168. PubMed ID: 28181959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study.
    Llorca PM; Bobes J; Fleischhacker WW; Heres S; Moore N; Bent-Ennakhil N; Sapin C; Loze JY; Nylander AG; Patel MX
    Eur Psychiatry; 2018 Aug; 52():85-94. PubMed ID: 29734130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs.
    Kumagai F; Suzuki T; Fleischhacker WW; Yasui-Furukori N; Mimura M; Uchida H
    J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.
    Sajatovic M; Levin J; Ramirez LF; Hahn DY; Tatsuoka C; Bialko CS; Cassidy KA; Fuentes-Casiano E; Williams TD
    J Clin Psychiatry; 2013 Dec; 74(12):1249-55. PubMed ID: 24434094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.
    Ascher-Svanum H; Zhao F; Detke HC; Nyhuis AW; Lawson AH; Stauffer VL; Montgomery W; Witte MM; McDonnell DP
    BMC Psychiatry; 2011 Sep; 11():152. PubMed ID: 21943257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
    Maestri TJ; Mican LM; Rozea H; Barner JC
    Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed.
    Meyer JM
    CNS Spectr; 2017 Dec; 22(S1):14-28. PubMed ID: 29350127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.
    Stroup TS; Bareis NA; Rosenheck RA; Swartz MS; McEvoy JP
    J Clin Psychiatry; 2018 Nov; 80(1):. PubMed ID: 30549494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial.
    Priebe S; Bremner SA; Lauber C; Henderson C; Burns T
    Health Technol Assess; 2016 Sep; 20(70):1-122. PubMed ID: 27682868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An interventional pilot of customized adherence enhancement combined with long-acting injectable antipsychotic medication (CAE-L) for poorly adherent patients with chronic psychotic disorder in Tanzania.
    Mbwambo J; Kaaya S; Lema I; Burant CJ; Magwiza C; Madundo K; Njiro G; Blixen CE; Cassidy KA; Levin JB; Sajatovic M
    BMC Psychiatry; 2022 Jan; 22(1):62. PubMed ID: 35086504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
    Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.